Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie

Riluzole [1744-22-5]

Drucken

Katalog-Nummer HY-B0211-500mg

Size : 500mg

Contact local distributor :

Telefonnummer : +1 850 650 7790

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :

Telefonnummer : +1 850 650 7790

Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC₅₀ of 43 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Riluzole Chemische Struktur

CAS. Nr. : 1744-22-5

This product is a controlled substance and not for sale in your territory.

Based on 9 publication(s) in Google Scholar

Other Forms of Riluzole:

Riluzole hydrochloride In-stock
Riluzole-¹³C,¹⁵N₂ Angebot einholen
Riluzole (Standard) Angebot einholen

Alle Isoformen anzeigen

Na_v1.1 Na_v1.2 Na_v1.3 Na_v1.4 Na_v1.5 Na_v1.6 Na_v1.7 Na_v1.8

Beschreibung

Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC₅₀ of 43 μM.

IC₅₀ & Target

Sodium channel^[1]
IC50: 43 μM (GABA receptor)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	> 25 μM Compound: 1b	Mitochondrial toxicity in human 786-O cells measured after 6 hrs by MitoTracker Red chloromethyl-X-rosamine based assay Mitochondrial toxicity in human 786-O cells measured after 6 hrs by MitoTracker Red chloromethyl-X-rosamine based assay	[PMID: 30908048]
A549	GI₅₀	10 μM Compound: 1b	Cytotoxicity against human A549 cells after 48 hrs by Celltiter-glo assay Cytotoxicity against human A549 cells after 48 hrs by Celltiter-glo assay	[PMID: 30908048]
CHO-K1	IC₅₀	310 μM Compound: Riluzole	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27287370]
CHO-K1	IC₅₀	480 μM Compound: Riluzole	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by LDH assay Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by LDH assay	[PMID: 27287370]
HEK293	IC₅₀	160 μM Compound: Riluzole	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method	[PMID: 21030469]
HEK293	IC₅₀	180 μM Compound: Riluzole	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method	[PMID: 21030469]
MRC5	ED₅₀	27.88 μg/mL Compound: 5c	Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay	[PMID: 21126022]

In Vitro

Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC₅₀ of 43 μM. At 20 μM, Riluzole inhibits peak autaptic IPSCs only slightly but prolongs IPSCs reliably. It is also found that Riluzole causes a strong, concentration-dependent, readily reversible enhancement of responses to 2 μM GABA. At higher concentrations of Riluzole, especially 300 μM, GABA currents exhibit apparent desensitization during prolonged co-exposure to 2 μM GABA and Riluzole. The EC₅₀ of Riluzole potentiation of GABA responses is about 60 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In normal na ve rats, systemic injection of Riluzole (8 mg/kg, i.p.; n=6 rats) decreases the duration of ultrasonic but not audible vocalizations evoked by noxious stimulation of the knee joint compare to vehicle tested in the same rats (P<0.05). Systemic application of Riluzole (8 mg/kg, i.p.; n=19 rats) decreases the vocalizations of arthritic rats compare to predrug and vehicle significantly (P<0.05 to 0.001). Riluzole administered into the CeA significantly decreases the duration of audible and ultrasonic vocalizations evoked by noxious stimulation of the knee compare to predrug values (n=8 rats; P<0.05 to 0.01)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Klinische Studie

Molekulargewicht

234.20

Formel

C₈H₅F₃N₂OS

CAS. Nr.

1744-22-5

Appearance

Solid

Color

White to yellow

SMILES

NC1=NC2=CC=C(OC(F)(F)F)C=C2S1

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (426.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (4.27 mM; ultrasonic and adjust pH to 3 with HCl)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.2699 mL	21.3493 mL	42.6985 mL
5 mM	0.8540 mL	4.2699 mL	8.5397 mL
10 mM	0.4270 mL	2.1349 mL	4.2699 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Reinheit & Dokumentation

Purity: 99.80%

Select Batch:

SDS (479 KB)

COA (245 KB) HNMR (127 KB) LCMS (136 KB)

Handling Instructions (2659 KB)

Verweise

[1]. He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199-209. [Content Brief]

[2]. Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 28;11:51. [Content Brief]

Zellassay ^[1]	Two-electrode voltage clamp of Xenopus oocytes expressing exogenous GABAA receptors is performed with a CA-1B high performance oocyte clamp. The extracellular recording solution is ND-96 medium. Riluzole is applied from a common tip via a gravity-driven multibarrel drug-delivery system. Data acquisition and analysis are performed with pCLAMP 6 software^[1]. MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.
Tierverwaltung ^[2]	Adult male Sprague-Dawley rats (180 to 350 g) are housed in a temperature-controlled room and maintained on a 12-h day/night cycle with unrestricted access to food and water. Pain behaviors are measured before and 5 h after induction of a mono-arthritis in the left knee joint. To test the effects of systemic (intraperitoneal, i.p.) application of Riluzole, pain behaviors are measured 1 h postinjection of Riluzole in normal and arthritic animals. To determine effects of Riluzole into the amygdala, pain behaviors are measured 15 min after starting Riluzole application through a stereotaxically implanted microdialysis probe. To investigate site of action in the amygdala of systemically applied Riluzole, potassium channel blockers are administered into the amygdala 45 min after systemic application of Riluzole and pain behaviors are measured 15 min later, i.e., 1 h postinjection of riluzole (i.p.)^[2]. MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.
Verweise	[1]. He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199-209. [Content Brief] [2]. Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 28;11:51. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	4.2699 mL	21.3493 mL	42.6985 mL	106.7464 mL
DMSO	5 mM	0.8540 mL	4.2699 mL	8.5397 mL	21.3493 mL
	10 mM	0.4270 mL	2.1349 mL	4.2699 mL	10.6746 mL
	15 mM	0.2847 mL	1.4233 mL	2.8466 mL	7.1164 mL
	20 mM	0.2135 mL	1.0675 mL	2.1349 mL	5.3373 mL
	25 mM	0.1708 mL	0.8540 mL	1.7079 mL	4.2699 mL
	30 mM	0.1423 mL	0.7116 mL	1.4233 mL	3.5582 mL
	40 mM	0.1067 mL	0.5337 mL	1.0675 mL	2.6687 mL
	50 mM	0.0854 mL	0.4270 mL	0.8540 mL	2.1349 mL
	60 mM	0.0712 mL	0.3558 mL	0.7116 mL	1.7791 mL
	80 mM	0.0534 mL	0.2669 mL	0.5337 mL	1.3343 mL
	100 mM	0.0427 mL	0.2135 mL	0.4270 mL	1.0675 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Riluzole Related Classifications

Membrane Transporter/Ion Channel Neuronal Signaling
Sodium Channel GABA Receptor

Riluzole [1744-22-5]

Katalog-Nummer HY-B0211-500mg

Contact local distributor :

Marke : MedChemExpress

Contact local distributor :

Other Forms of Riluzole:

Molaritätsrechner

Verdünnungsrechner

Complete Stock Solution Preparation Table

Riluzole Related Classifications

Keywords:

Sie könnten auch an folgenden Produkten interessiert sein:

Riluzole [1744-22-5]

Katalog-Nummer HY-B0211-500mg

Contact local distributor :

Marke : MedChemExpress

Contact local distributor :

Other Forms of Riluzole:

Riluzole Related Antibodies

Molaritätsrechner

Verdünnungsrechner

Complete Stock Solution Preparation Table

Riluzole Related Classifications

Keywords:

Sie könnten auch an folgenden Produkten interessiert sein: